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ORIGINAL ARTICLE

Plasma REST: a novel candidate biomarker of
Alzheimer’s disease is modiﬁed by psychological
intervention in an at-risk population
NJ Ashton1,2,7, A Hye1,2,7, CA Leckey1,2, AR Jones1, A Gardner3, C Elliott1, JL Wetherell4,5, EJ Lenze6, R Killick1,8 and NL Marchant1,3,8
The repressor element 1-silencing transcription (REST) factor is a key regulator of the aging brain’s stress response. It is reduced in
conditions of stress and Alzheimer’s disease (AD), which suggests that increasing REST may be neuroprotective. REST can be
measured peripherally in blood plasma. Our study aimed to (1) examine plasma REST levels in relation to clinical and biological
markers of neurodegeneration and (2) alter plasma REST levels through a stress-reduction intervention—mindfulness training. In
study 1, REST levels were compared across the following four well-characterized groups: healthy elderly (n = 65), mild cognitive
impairment who remained stable (stable MCI, n = 36), MCI who later converted to dementia (converter MCI, n = 29) and AD (n = 65)
from the AddNeuroMed cohort. REST levels declined with increasing severity of risk and impairment (healthy elderly4stable
MCI4converter MCI4AD, F = 6.35, P o 0.001). REST levels were also positively associated with magnetic resonance imaging-based
hippocampal and entorhinal atrophy and other putative blood-based biomarkers of AD (Pso 0.05). In study 2, REST was measured
in 81 older adults with psychiatric risk factors for AD before and after a mindfulness-based stress reduction intervention or an
education-based placebo intervention. Mindfulness-based training caused an increase in REST compared with the placebo
intervention (F = 8.57, P = 0.006), and increased REST was associated with a reduction in psychiatric symptoms associated with stress
and AD risk (Pso 0.02). Our data conﬁrm plasma REST associations with clinical severity and neurodegeneration, and originally, that
REST is modiﬁable by a psychological intervention with clinical beneﬁt.
Translational Psychiatry (2017) 7, e1148; doi:10.1038/tp.2017.113; published online 6 June 2017

INTRODUCTION
The repressor element 1-silencing transcription (REST) factor,
alternatively named neuron-restrictive silencing factor (NRSF), is a
protein that modulates neuronal differentiation and gene expression, and has recently been found to play an important role in
Alzheimer’s disease (AD) neuropathology. Though highly
expressed during development, REST was thought to be quiescent
in the adult brain. However, recent observations indicate REST
expression reactivated in the aging brain.1 REST has been shown
to protect mature hippocampal neurons from toxic insults, for
example, hyperexcitation,2 and to play a key role in regulating the
aging brain’s response to stress.1 Furthermore, preclinical and
clinical evidence demonstrate that reduced brain REST levels are
associated with reductions in hippocampal volume and increased
cognitive impairment.1 Conversely, individuals carrying signiﬁcant
amyloid- and tau-based neuropathologies, the classic deﬁning
hallmarks of AD, but who also have elevated REST, do not advance
to a clinical diagnosis of dementia.1 These observations indicate
that REST may act as a neuronal protective factor in older adults,
by suppressing genes that drive neurotoxic processes resulting in
cognitive decline and neuronal death.

REST presents a promising novel candidate biomarker for AD.
However, its detection only in the central nervous system or in
in vitro models has limited its utility as a translational research tool.
Recently, however, REST has been identiﬁed in neuronally derived
exosomes in blood, with diminishing levels shown to be clinically
signiﬁcant,3,4 but the methods of exosome isolation can be a
laborious and variable process thereby limiting its utility for
translational research. These earlier studies have aimed to
measure REST levels in neuronally derived exosomes by isolating
them from plasma by afﬁnity puriﬁcation with an L1-CAM (CD171)
antibody. While this protocol has been used routinely to
successfully isolate exosomes, in this context it may prove
problematic, given L1-CAM gene expression and splicing is known
to be regulated by REST.5 Therefore, it is unclear how perturbed
REST expression may alter the levels and forms of L1-CAM
expressed on neuronal exosomes. To circumvent this, we elected
to measure total peripheral REST in both membrane-bound
vesicles and free forms simultaneously in patient plasma,
particularly as the latter has yet to be fully explored. Our strategy
therefore provides a highly comprehensive, reproducible and
unbiased approach, which can be readily applied to large cohortbased studies.
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The concept of cognitive debt identiﬁes psychological risk
factors for AD, including depression and anxiety, which are
associated with dysregulated stress responses.6,7 However, these
risks have not been consistently associated with classic AD
pathology.6 Cognitive debt supports a model of AD in which
psychological stress is a contributory factor for the disease and
proposes that reducing stress in individuals with high cognitive
debt (for example, clinical depression and/or anxiety) will lower
the incidence of AD. The identiﬁcation of novel biomarkers that
can provide a mechanistic/molecular link between these psychological risks and AD are needed to better understand the disease.
REST is dysregulated in depression, a psychological ‘stress’
disorder with increased risk for AD.8,9 Given its involvement in
stress responses, REST may therefore be the biological mediator
between psychological risk factors and AD.
Stress-reducing interventions may alleviate some of these
dysregulated stress responses. Mindfulness-based stress reduction
(MBSR) is an intervention that emphasizes focused, nonjudgmental awareness of present moment experiences.10 Preliminary
ﬁndings in the elderly show that mindfulness-based training
improves cognitive function in domains most sensitive to aging
and AD,11,12 and can reduce stress, anxiety and depression.6,13,14
Given that MBSR focuses on reducing stress, we hypothesized
that this intervention would promote neural protection by
targeting REST.
In this present study, we sought to detect circulating peripheral
REST in two studies of older adults in order to investigate the
following three questions: (1) are REST levels different between
healthy elderly controls (HECs) and patients with mild cognitive impairment (MCI) and AD; (2) and are they associated
with surrogate markers of AD; (3) can REST levels be modiﬁed
by a stress-reducing intervention in older adults with high
cognitive debt.
MATERIALS AND METHODS
Cohorts
AddNeuroMed. The AddNeuroMed (ANM) project, part of InnoMed
(Innovative Medicines in Europe), is a multicenter European program
designed to develop and validate novel surrogate markers of AD that
combines magnetic resonance imaging (MRI) data with other putative
biomarker and clinical data. Detailed information on the study design and
enrollment procedures of ANM have been previously discussed.15 The
diagnosis of probable AD was made as follows. Inclusion criteria: (1)
ADRDA/NINCDS and DSM-IV criteria for probable AD. (2) Mini Mental State
Examination (MMSE) scores ranging between 12 and 28. (3) Age 65 years
or above. Exclusion criteria: (1) signiﬁcant neurological or psychiatric illness
other than AD. (2) Signiﬁcant unstable systemic illness or organ failure. All
AD participants had a Clinical Dementia Rating scale score of 0.5 or above.
The diagnosis of MCI was made according to the Peterson criteria.16
Intervention cohort. Participants were 103 adults aged 65 or older, 81 of
whom provided blood samples before and after the intervention. Details of
this cohort and the intervention have previously been reported.17 Brieﬂy,
participants with (1) clinically signiﬁcant anxiety or depressive symptoms,
and (2) a current diagnosis of a depressive and/or anxiety disorder and (3)
who endorsed current subjective aging-related neurocognitive problems
were recruited into a clinical trial to examine effects of MBSR versus a
comparison condition on cognitive function and psychiatric symptoms.
Exclusion criteria: a diagnosis of dementia or dementia symptoms
(ascertained from the Short Blessed Test18), prescription of cognitive
enhancing medication, alcohol or substance use disorders within the past
6 months, current or lifetime psychotic or bipolar disorder, current
participation in psychotherapy or regular engagement in mindfulness
practice or yoga, corticosteroid use, and serious medical illness that would
prevent study participation or accurate data collection (for example,
congestive heart failure, oxygen dependent). Individuals currently taking
antidepressants or anxiolytics were eligible if they had been on a stable
dose for at least a month prior to enrollment and agreed to remain stable
throughout the intervention.
Translational Psychiatry (2017), 1 – 8

Interventions
Participants were randomized in groups of ﬁve to eight people to either
MBSR or to a health education control condition. The 8-session MBSR
intervention was conducted according to the protocol developed by Jon
Kabat-Zinn,19 modiﬁed for older patients, along with a half-day meditation
retreat. The health education comparison intervention was based on the
health care self-management book written by Lorig et al.20 The 8-session
program included topics on understanding and managing common
conditions and symptoms, healthy eating, managing medications and
communicating with health care providers. Both the MBSR and health
education programs were once weekly, group-based sessions of ~ 90 min.
Participants in both groups received manuals and had between-session
assignments (more details about the interventions can be found in Lenze
et al.17).

Blood collection and processing
Blood samples from both cohorts were drawn by venipuncture at the time
of assessment (baseline and post intervention for the Intervention cohort).
ANM participants were required to fast for at least 2 h before collection.
Blood samples were centrifuged at 3000 g for 10 min at 4 °C. Blood
samples from the Intervention cohort (non-fasting) were centrifuged at
3000 g for 15 min. Plasma supernatant was collected, divided into aliquots
and frozen at − 80 °C until further use. All samples were centrifuged within
2 h of collection. The APOE single-nucleotide polymorphisms (SNPs)
rs429358 and rs7412 were genotyped using Taqman SNP genotyping
assays (determined by allelic discrimination assays based on ﬂuorogenic 5′
nuclease activity) and the allele inferred.

Immunological assays
Plasma REST was quantiﬁed using a sandwich enzyme-linked immunosorbent assay, Cusabio, American Research Products (College Park, MD, USA),
in both studies. Plasma samples were pretreated with Tween-20 (4% v/v)
to release REST contained within extracellular vesicles and mixed on an
orbital shaker for 15 min prior to primary antibody incubation. Plasma
samples were measured in duplicate and mean absorbance values
(450 nm) exported into Sigma plot (Systat Software, London, UK; version
12) for estimation of protein concentrations using a ﬁve-parameter logistic
ﬁt. To assess the performance of the enzyme-linked immunosorbent assay
the intra- and inter-assay coefﬁcient of variance (CV%) were calculated for
both the cohorts. The investigator who ran the immunological assays was
blind to clinical condition (in the ANM cohort) and intervention group (in
the Intervention cohort).
Other candidate plasma proteins had been previously assayed in the
ANM cohort by using multiplex bead assays (Luminex xMAP, Austin, TX,
USA).21 We investigated the association of REST with 16 proteins observed
as markers of AD disease severity and conversion21 in the ANM cohort.
Proteins associated with REST in the ANM cohort were then examined in
the Intervention cohort using the same technique.

Cognitive and clinical assessments
In the Intervention cohort, memory was assessed by immediate and
delayed paragraph and list recall.22 Executive function was assessed by the
Delis–Kaplan Executive Function System (DKEFS) Verbal Fluency test and
the DKEFS Stroop test.23 These cognitive assessments were conducted at
baseline and post intervention (8 weeks). For each time point, composite
scores for memory and executive function were created by averaging Zscores for each measure. The Wechsler Test of Adult Reading (WTAR)24 was
administered to assess premorbid neurocognitive function at baseline.
Clinical assessments made using subscales of the PROMIS questionnaire
included assessments of subjective cognitive concerns, anxiety and
depression25 Chronic worry was assessed by the Penn State Worry
Questionnaire-Abbreviated.26 Clinical assessments conducted at baseline
and post intervention (8 weeks) were used for analyses.

Magnetic resonance imaging
A description of MRI procedures in the ANM cohort has been previously
described.21 High-resolution sagittal 3D T1-weighted magnetization
prepared rapid gradient-echo (MPRAGE) volume (voxel size
1.1 × 1.1 × 1.2 mm3) was acquired on 1.5 T MRI scanners for 148/195 of
the ANM sub-cohort.27 Measures of hippocampal volume, entorhinal
cortex volume, ventricular volume and whole brain volume were chosen as
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MRI endophenotypes of AD. Participants in the Intervention cohort did not
receive MRI scans.

Statistical analysis
Statistical analyses and ﬁgures were processed using SPSS 22 (IBM,
Armonk, NY, USA) and R software. REST concentrations in both cohorts
were non-normally distributed and were log10-transformed except for
ANM REST in the Tobit model. When reporting REST mean and s.d.’s, we
report the original pg ml − 1 values.
Age, sex, assay plate, plasma storage duration (days) and center were
examined as covariates in the ANM cohort. REST was signiﬁcantly affected
by assay plate and center. To analyze differences in REST in the ANM
cohort, we implemented a Tobit model, using a left-censored value of
25.63 (the lowest recorded REST pg ml − 1), diagnosis (controls, cMCI, sMCI
and AD) as a predictor variable, and adjusted for dummy variables assay
plate and center code. The relationship between APOE and REST was
examined separately using non-parametric testing.
In the Intervention cohort, REST was signiﬁcantly affected by assay plate
and center, and age differed between the two conditions; therefore REST
values were adjusted for these variables using a generalized linear
regression model (GLM). All subsequent analyses were performed on the
GLM-adjusted (non-standardized residuals) data. To analyze differences in
REST pre- and post intervention in the Intervention cohort, we used a
linear-mixed model (ﬁtted with restricted maximum likelihoods) with
intervention condition (MBSR and health education) and time (pre- and
post intervention) as predictor variables, condition × time as an interaction
term and time grouped by participant as random effects. For this analysis,
we are primarily interested in whether the pre- and post-intervention
changes in REST concentration change depending on condition. Post hoc
analyses of interactions for the Intervention cohort were performed using
pairwise comparison of least square means of log-transformed REST values;
non-adjusted P-values are reported. REST, cognitive and clinical data in the
Intervention cohort were also divided into ‘change’ categorical variables
(increase, decrease) by subtracting baseline from post-intervention levels.
If a REST was below the detectable range at baseline and was within the
detectable range post intervention this was classiﬁed as an ‘increase’,
likewise a sample was classiﬁed as ‘decrease’ if it was detectable at

Table 1.

baseline but not post intervention. Chi-square analyses were conducted on
categorical data.
Partial correlation analysis was performed to examine REST level
associations with structural MRI brain imaging (ANM only), baseline
cognitive and clinical data (Intervention cohort) or additional proteomic
data (ANM and Intervention cohort). Benjamini–Hochberg Q-values were
calculated as a multiple testing correction.

RESULTS
REST and clinical group (AddNeuroMed)
The impetus for the present study was to investigate REST as a
possible blood-based biomarker of the stress response mechanism in AD. To achieve this aim, we examined whether REST was
detectable in blood (plasma), and if patients classiﬁed as HECs and
clinically deﬁned AD showed differential REST expression. In a
feasibility study (n = 62; Supplementary Table S1) in the ANM
cohort, we demonstrated that REST levels were quantiﬁable in
plasma in 71% of the sample. Further, REST levels were reduced in
AD (M = 46.77 pg ml − 1, s.d. = 2.05) compared to HEC
(M = 89.13 pg ml − 1, s.d. = 2.63; t(60) = 3.03, P = 0.003) and signiﬁcantly more AD REST levels were below the limits of detection
than HEC (χ2(1) = 7.82, P = 0.005). Due to a number of the AD
samples falling below the detection level, we further investigated
the prospect of REST being located in extracellular vesicles—this
has been previously reported.3,4 By pre-treating plasma samples,
we sought to mobilize REST from microvesicles, thereby releasing
REST into the soluble space. In the AD group a 61.39% increase in
REST signal (M = 110.01 pg ml − 1, s.d. = 2.63) and increase in the
number of samples above limits of detection were observed. The
HECs group also demonstrated a substantial increase in REST
signal (115.17%, M = 222.43 pg ml − 1), thus demonstrating REST as
both contained within microvesicles and circulating freely in
blood (plasma). This is of particular signiﬁcance, as previous
studies have focused mainly on REST contained in microvesicles
and therefore have not measured free REST levels.

Demographic and clinical data from (a) ANM sub-cohort and (b) Intervention sub-cohort

(a) ANM sub-cohort
Participants, n (%)
Age, mean years (s.d., range)
Sex, n females (%)
MMSE, mean (s.d., range)
CDR sum of boxes, mean (s.d., range)
APOE ε4 carrier, n (%)
Years to conversion, mean (s.d., range)

HEC

sMCI

cMCI

AD

P-value

65 (33)
75.7 (8.6, 53–89)
33 (50.8)
29 (1.1, 27–30)
0.01 (0.1, 0–0.5)
23 (35.4)
NA

36 (18)
76.8 (8, 65–89)
15 (41.7)
27 (1.9, 21–30)
0.47 (0.1, 0–0.5)
9 (25.7)
NA

29 (15)
75.4 (7.1, 57–89)
17 (58.6)
25.7 (2.4, 18–30)
0.48 (0.1, 0–0.5)
17 (56.7)
1.06 (0.22, 0.95–2.11)

65 (33)
76.8 (8, 61–90)
33 (50.8)
19.6 (4.1, 12–26)
1.3 (0.7, 0.5–3)
32 (49.2)
NA

NS
NS
NS
o 0.001a
o 0.001b
o 0.05c
NA

Total sample

MBSR

Health education

P-value

Demographics
Participants, n (%)
Age, mean (s.d., range)
Sex, n females (%)
Education, mean years (s.d., range)
APOE ε4 carrier, n (%)

81 (100)
72.1 (5.7, 65–89)
58 (71.6)
15.8 (2.8, 6–20)
26 (32.1)

30 (37)
70.2 (4.2, 65–79)
22 (73.3)
16.0 (3.0, 6–20)
10 (33.3)

51 (63)
73.3 (6.2, 65–89)
36 (70.6)
15.7 (2.6, 8–20)
16 (31.4)

0.03
NS
NS
NS

Baseline clinical and cognitive measures
Short Blessed, mean (s.d., range)
WTAR Raw, mean (s.d., range)
PROMIS anxiety, mean (s.d., range)
PROMIS depression, mean (s.d., range)
PROMIS cognitive concerns, mean (s.d., range)
Penn State Worry Questionnaire-Abbreviated, mean (s.d., range)

1.7 (2.1, 0–9)
40.2 (8.4, 8–50)
20 (5.8, 7–31)
19.9 (7.2, 8–36)
23.2 (7.4, 8–40)
27.6 (7.7, 8–50)

1.7 (1.6, 0–6)
39.3 (8.5, 23–49)
20.7 (5.8, 8–31)
20.5 (7.9, 8–36)
24.2 (9.0, 8–40)
28.4 (6.4, 9–37)

1.9 (2.3, 0–9)
40.6 (8.4, 8–50)
19.6 (5.8, 7–29)
19.6 (6.8, 8–35)
22.7 (6.2, 10–36)
27.2 (8.3, 8–40)

NS
NS
NS
NS
0.004
0.09

(b) Intervention sub-cohort

Abbreviations: AD, Alzheimer’s disease; ANM, AddNeuroMed; CDR, Clinical Dementia Rating; cMCI, converting mild cognitive impairment; HEC, healthy elderly
control; MBSR, mindfulness-based stress reduction; MMSE, Mini Mental State Examination; NA, not applicable; NS, not signiﬁcant; sMCI, stable mild cognitive
impairment; WTAR, Wechsler Test of Adult Reading. aSigniﬁcant across all four groups. bSigniﬁcant across all groups except between sMCI and cMCI.
c
Signiﬁcant only between sMCI and cMCI.
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Figure 1. Repressor element 1-silencing transcription (REST) values stratiﬁed by clinical diagnosis. Log10-transformed REST values
(corrected for assay plate and center) are represented as means (s.e.m. error bars). (a) There was a signiﬁcant decline in REST from
healthy elderly controls (HEC) to mild cognitive impairment (MCI) to Alzheimer’s disease (AD). Compared with the AD group, the MCI
group showed signiﬁcantly higher levels of REST (+95.73, 95% CI 1.82–189.65, P = 0.046) as did the control group (+122.45, 95%
CI 27.96–216.93, P = 0.011). (b) Dividing mild cognitive impairment groups into those who remained stable (sMCI) and those who later
converted to AD (cMCI), compared with the AD group, REST levels were not signiﬁcantly different in the cMCI group (26.00, 95%
CI − 90.67–142.68, P = 0.66) but were signiﬁcantly higher in the sMCI group (159.06, 95% CI 47.77–270.65, P = 0.005) and controls (126.12, 95%
CI 32.53–219.70, P = 0.008).

We then sought to conﬁrm this initial ﬁnding in a signiﬁcantly
larger selection of participants from the ANM cohort (n = 195),
expanded to include individuals with MCI who remained stable
(sMCI) or later converted to AD (cMCI). Table 1a describes the
demographic characteristics of ANM. An even distribution of
clinical diagnosis was selected (AD = 65, sMCI = 35, cMCI = 30,
HEC = 65), matched for age and sex.
In total, 168/195 (86%) participants had quantiﬁable REST and
intra- and inter-assay were 9.2% and 14.6% CV, respectively. The
AD group as before had lower REST levels (M = 112.12 pg ml − 1, s.
d. = 2.21) than HECs (M = 199.21 pg ml − 1, s.d. = 2.32). The MCI
group as a whole showed lower REST compared with HECs group
(M = 193.51 pg ml − 1, s.d. = 2.56). There was a signiﬁcant decline in
REST from HECs to MCI to AD (Figure 1a). Using the AD cohort as
the comparator, the MCI group showed signiﬁcantly higher levels
of REST (+95.73, 95% CI 1.82–189.65, P = 0.046) as did the control
group (+122.45, 95% CI 27.96–216.93, P = 0.011).
We next divided the MCI group into those who remained stable
(sMCI, M = 207.83 pg ml − 1, s.d. = 3.03) and those who later
converted to AD (cMCI, M = 179.23 pg ml − 1, s.d. = 2.06) and
repeated the analyses. Using the AD group as the comparator,
REST levels were not signiﬁcantly different from the cMCI
group (26.00 pg ml − 1, 95% CI − 90.67 to 142.68, P = 0.66);
however, the sMCI group (159.06 pg ml − 1, 95% CI 47.77 to
270.65, P = 0.005) and controls (126.12 pg ml − 1, 95% CI 32.53 to
219.70, P = 0.008) had signiﬁcantly higher levels of REST
(Figure 1b). APOE genotype had a signiﬁcant effect on REST
levels (U = 2733.00, P = 0.02) when examined in isolation, but
Translational Psychiatry (2017), 1 – 8

Table 2. MRI brain structures and candidate plasma proteins of
cognitive decline and disease risk associated with REST values in the
ANM cohort

MRI brain structures
Mean hippocampal
volume
Mean entorhinal
cortex volume
Ventricle volume
Whole brain volume

P-value Q-value

df

Correlation
coefﬁcient with
REST

122

0.246

0.013

0.025

122

0.295

0.003

0.013

122
102

−0.179
0.213

0.060
0.030

NS
0.038

0.022
0.039
0.002
0.001
40.001
0.004

NS
NS
0.006
0.004
0.002
0.008

Signiﬁcant candidate plasma proteins21
ApoA1
164
0.178
ApoC3
162
0.162
BDNF
125
0.267
NSE
162
0.284
PAI-1
159
0.286
RANTES
162
0.224

Abbreviations: ANM, AddNeuroMed; ApoA1, Apolipoprotein A1; ApoC3,
Apolipoprotein C3; BDNF, Brain-derived neurotrophic factor; MRI, magnetic
resonance imaging; NS, not signiﬁcant; NSE, neuron-speciﬁc enolase; PAI-1,
plasminogen activator inhibitor type 1; RANTES, regulated on activation,
normal T cell expressed and secreted; REST, repressor element 1-silencing
transcription.
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Figure 2. Change in repressor element 1-silencing transcription (REST) values stratiﬁed by intervention condition. Log10-transformed REST
values were corrected for assay plate, center and age. There was a signiﬁcant interaction between condition and time (F = 5.78, P = 0.02). (a)
Box and whiskers plot of change in mean REST levels (post intervention minus baseline). (b) Spaghetti plot of baseline and post intervention
REST levels of participants who showed a decrease in REST. (c) Spaghetti plot of baseline and post intervention REST levels of participants who
showed an increase in REST.

Figure 3. Frequency plot of participants showing an increase or decrease in repressor element 1-silencing transcription (REST) after the
intervention, stratiﬁed by change in psychiatric symptoms of depression and anxiety. An increase in REST was signiﬁcantly associated with
improvement in symptoms of (a) depression (χ2 = 6.86, P = 0.03) and (b) anxiety (χ2 = 9.78, P = 0.008).

adding genotype as a covariate to the between group comparisons did not alter the ﬁndings.
REST and surrogate AD markers
Partial correlation analyses, co-varying for APOE genotype,
demonstrated associations with hippocampal volume, entorhinal
cortex volume, whole brain volume and a trend toward
signiﬁcance for ventricular volume (Table 2). In addition, we
investigated REST level associations with 25 plasma proteins
previously associated with either cognitive decline or disease
severity.21 REST had a positive correlation with ApoC3 and ApoA1,
brain-derived neurotrophic factor (BDNF), regulated on activation,
normal T cell expressed and secreted (RANTES), plasminogen
activator inhibitor-1 (PAI-1) and neuron-speciﬁc enolase (NSE)
(Table 2). After adjusting for multiple comparisons, REST associations with hippocampal volume, entorhinal cortex volume, whole
brain volume, BDNF, RANTES, PAI-1 and NSE remained statistically
signiﬁcant (Table 2).

REST modiﬁcation (Intervention cohort)
Demographic, clinical and cognitive characteristics of participants
randomized to the MBSR condition were not statistically different
from those in the control condition; however, they were aged
slightly younger (Table 1b).
REST was detectable in 52 baseline samples and 51 postintervention samples, with 37 participants having quantiﬁable
REST at both time points and performed in line with the ANM
cohort with 8.5% (intra) and 12.3% (inter) CV. Correlation analyses
revealed that baseline REST was not associated with anxiety or
depressive symptoms, worry, cognitive concerns, scores on the
short blessed cognitive test or measures of executive function or
memory (P’s40.05).
We tested whether changes in REST occurred between
pre- and post intervention (time) differently for the MBSR
group compared to controls. We found a signiﬁcant interaction
between condition and time (F = 5.78, P = 0.02). Initially there was
signiﬁcant difference in REST between MBSR patients and controls
pre-intervention (−0.23, s.e. = 0.10, P = 0.027, REST difference
Translational Psychiatry (2017), 1 – 8
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− 34.10 pg ml − 1) but not post intervention (−0.06, s.e. = 0.10,
P = 0.504, REST difference − 9.52 pg ml − 1). This is due to a nearsigniﬁcant increase in REST pre-intervention to post intervention
for MBSR patients (0.19, s.e. = 0.10, P = 0.055, REST difference
+38.70 pg ml − 1), which was not present for pre- to post changes
in REST for the controls (−0.11, s.e. = 0.08, P = 0.178, REST
difference − 8.60 pg ml − 1, Figure 2a). Individual data are shown
in Figures 2b and c. Controlling for sex and/or APOE status did not
alter the results.
Treating data as categorical variables, an increase in REST was
signiﬁcantly associated with improvement in symptoms of
depression (χ2 = 6.86, P = 0.03, Figure 3a) and anxiety (χ2 = 9.78,
P = 0.008, Figure 3b), irrespective of intervention condition,
but not with memory, executive function, cognitive concerns
or worry.
In this data set, we independently conﬁrmed the strong
association of REST with other candidate plasma proteins of
cognitive decline at baseline: BDNF (r = 0.5, P o 0.001), RANTES
(r = 0.421, P = 0.002) and PAI-1 (r = 0.321, P = 0.026). However, none
of these putative markers displayed any signiﬁcant change after
the intervention.
DISCUSSION
This study indicates that blood REST protein levels are a novel,
psychologically modiﬁable candidate biomarker of cognitive
decline and AD.28 Peripherally circulating REST levels declined
with increasing clinical severity, resulting in AD patients showing
the lowest levels. Patients with MCI who later converted to AD
exhibited an ‘Alzheimer’s-like’ REST proﬁle, whereas nonconverters (stable) MCI participants had a REST proﬁle that
resembled HECs. Importantly, we demonstrated that REST levels
can be modulated through a relatively brief behavioral stressreduction intervention, and that changes in REST are associated
with clinical improvements.
Our ﬁnding of reduced REST in AD participants mirrors the
neural loss of REST in autopsy-conﬁrmed AD patients.1 In support
of these ﬁndings, a decrease in REST levels contained within
neuronally derived exosomes has previously been reported in
small sample of patients with AD and MCI compared with elderly
participants.3,4 Here we demonstrated that a substantial proportion of REST is located outside these extracellular vesicles and is
free-ﬂoating in plasma. By releasing membrane-enclosed REST
into the soluble space, we measured total REST and increased the
signal of REST considerably, contributing to the strong linear
decline of REST with increasing severity of cognitive deﬁcits and
clinical diagnosis. It must be acknowledged, however, that
REST can be expressed in multiple cell types in the periphery,
so until a direct comparison of peripheral and central REST levels
can be made, it remains unclear whether REST measured here
indeed reﬂect levels in the central nervous system. Nevertheless,
these ﬁndings strongly support that our method is capable of
measuring low abundant proteins quickly and efﬁciently, thus
avoiding the time consuming preparation of exosomes. Our
unbiased approach also circumvents technical limitations of
exosome enrichment particularly when using neuronal adhesion
molecules, such as L1CAM, whose expression and splicing are
regulated by REST.
Using MRI as a surrogate marker of disease pathology, we found
REST associations with several brain regions impacted early in AD
—hippocampal and entorhinal cortices. Controlling for APOE
genotype did not alter the association with REST and MRI
measures or clinical status, indicating that REST may be a speciﬁc
marker of AD risk, independent of APOE genotype.
Investigating the association of REST with previously identiﬁed
plasma protein markers of MCI conversion to AD and cortical
atrophy,21 we found strong associations with BDNF, RANTES, PAI-1
and NSE. These associations were conﬁrmed, independently, in
Translational Psychiatry (2017), 1 – 8

the Intervention cohort. There is evidence that, like REST, BDNF
has a neuroprotective role in the presence of pathological
conditions.29 Decreased BDNF expression in the AD brain has
been shown30 and several studies have observed a decrease of
peripheral BDNF in MCI and AD patients,31–33 including in a metaanalysis of 7277 subjects.34 Indeed, higher BDNF serum levels have
shown to protect against the future incidence of AD.35 In addition,
sequence variations in the BDNF gene have been conﬁrmed to be
connected with neurological disorders such as major depression.36
While recently, both REST and BDNF have been associated with
cognitive dysfunction in epilepsy sufferers.37 In this study, we
have shown a decrease in BDNF in AD and MCI, and a strong
relationship between REST and BDNF in two independent cohorts.
NSE in blood is considered to be a peripheral biomarker of
neuronal injury38 and blood–brain barrier dysfunction,39 and PAI-1
has been strongly linked with aging,40 remitted depression41 and
severe anxiety.42 Given the relationship we have shown between
these three markers and REST plus their involvement in psychological disorders carrying increased risk for AD, in combination,
REST, BDNF, NSE and PAI-1 may provide a more sensitive predictor
of cognitive decline than a single peripheral protein.
Of major interest we report that in older adults at risk of
developing dementia, a signiﬁcant increase in REST levels was
induced by a stress reduction intervention after just 8 weeks,
potentially highlighting REST as a modiﬁable target. REST is known
to highly regulate the cortisol levels via the modulation of
CYP11B1 gene,43 thus, the intervention may have modiﬁed
cortisol levels, which in turn inﬂuenced the REST levels.
Furthermore, individuals showing an increase in REST also had a
reduction in symptoms of anxiety and depression, which indicates
a mechanistic link between REST, stress and psychological risk
factors for AD. These ﬁndings are also supported by previous
research showing a relationship between reduced REST expression
and depression,8 and suggest that interventions targeting REST
would have clinical utility. No association was found between
REST and cognition, possibly as the intervention was too brief for
such changes to occur or the limited ability to detect cognitive
improvements.
A larger study with a longer follow-up will be needed to clarify
the clinical implication of this REST increase with MBSR, but our
study has demonstrated, using a rigorously controlled design, that
REST does in fact increase with MBSR.
The participant-inclusion criteria of the two cohorts included in
this study either exclusively recruited individuals without the
presence of a psychiatric disorder (for example, depression,
anxiety, ANM) or with a psychiatric disorder (Intervention cohort),
therefore in this study we were unable to directly compare REST
levels in depressed/anxious versus healthy older adults. Due to
this constraint, the direct link between cognitive debt and this
novel biological marker has not yet been investigated.
Population-based measures of REST in varying ages and clinical
conditions need to be reﬁned before any cutoff of clinical
signiﬁcance is proposed. The development of an assay that is
robust and consistent in quantifying low values of REST would be
a critical ﬁrst step. Nonetheless the results are a promising
indicator that reducing stress raises REST levels in blood and, by
inference may also increase levels in brain too; something we aim
to determine in future studies.
Notwithstanding the above limitations, we were able to show
that REST is associated with disease state and surrogate markers
for disease, REST can be modiﬁed using a behavioral intervention
and that increased REST is associated with a reduction in
psychological risk factors for AD, indicating the utility of this
marker. Indeed, the failure of the brain’s stress response system
via REST is now being considered as an alternative therapeutic
target for AD.1,44 A search for a blood-based surrogate of AD
pathology, in particular neocortical amyloid burden, to compliment participant recruitment into AD therapeutic trials is
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ongoing.45,46 Aging individuals who exhibit substantial AD
pathology appear to be protected from dementia when neuronal
REST levels are high and therefore, AD structural pathology may
not be sufﬁcient to cause dementia. The ﬁndings presented here
are of great signiﬁcance for the diagnosis and clinical management of AD, as determining REST in blood provides a prognostic
marker that can help stratify patients for inclusion in trials, identify
those at high risk of ‘stress-induced’ cognitive decline and
determine the efﬁcacy of therapeutic interventions. Dysregulation
of REST provides an insight into the underlying processes leading
to AD by which aging factors in the brain lead to cognitive decline.
Therefore, further elucidation of these mechanisms will provide
targets for the development of novel therapeutic strategies.
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